Juvena Therapeutics Raises $41M in Series A Funding

Juvena Therapeutics, a Redwood City, CA-based biotechnology company, raised $41M in Series A funding.

The round was led by Mubadala Capital and Horizons Ventures, with participation from Bison Ventures, Manta Ray Ventures, IRONGREY, Alumni Ventures, Plum Alley, Jeff Dean, Transform VC, Karl Pfleger, BoxOne Ventures, Intersect VC, Compound, and Felicis.

The company intends to use the funds for the expansion of its drug discovery platform and advance its biologics pipeline targeting chronic and age-related diseases.

Co-founded by Dr. Hanadie Yousef, and Dr. Jeremy O’Connell, Juvena Therapeutics is a biotech company accelerating the development of therapeutics by unlocking the therapeutic potential of secreted proteins. Secreted proteins are a class of biologics with proven therapeutic potential that has been under-leveraged due to the complexity of identifying and screening such proteins. The company is developing a patent-pending computational drug discovery and development platform that is delivering novel biologics to address major unmet medical needs in chronic and age-related diseases by mining regenerative proteins secreted by stem cells.

As the company expands its platform, it is also accelerating its preclinical programs, having secured funding from the California Institute of Regenerative Medicine and the National Institute of Health for the treatment of Myotonic Dystrophy Type 1, a rare disease that is incurable today.

FinSMEs

08/11/2022